YOLFTbeta
Kamada

Kamada

KMDA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

8.09USD-0.04 (-0.49%)

Price History

Full chart

Market Stats

Previous Close8.13
Open8.22
Day Range8.00 – 8.31
52-Week Range6.18 – 8.96
Volume94.47K
Market Cap503.23M
P/E (TTM)22.95
Forward P/E16.53
EPS0.38
Dividend Yield1.95%
Beta0.14
50-Day Avg7.80
200-Day Avg7.93

About

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Amir London
  • Employees462
  • Headquarters2 Holzman Street, Rehovot, Israel, 7670402, USA
  • Websitehttps://www.kamada.com

Leadership

  • Mr. Amir LondonChief Executive Officer · b. 1969
  • Mr. Chaime OrlevChief Financial Officer · b. 1970
  • Mr. Eran NirChief Operating Officer · b. 1973
  • Mr. Jon R. KnightVice President of US Commercial Operations · b. 1966
  • Mr. Boris GorelikVice President of Business Development & Strategic Programs · b. 1982
  • Mr. David TsurCo-Founder & Independent Deputy Chairman of the Board · b. 1950
  • Mr. Nir Livneh B.A., L.L.B.VP, General Counsel & Corporate Secretary · b. 1979
  • Ms. Hanni NehemanVice President of Marketing & Sales · b. 1970
  • Ms. Liron ReshefVice President of Human Resources · b. 1972
  • Ms. Shavit BeladevVice President of Kamada Plasma · b. 1971

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue13.44M15.21M14.98M36.27M55.92M72.67M70.62M71.92M70.11M77.49M102.83M114.47M127.19M133.25M103.64M129.34M142.52M160.95M180.46M
Growth (%)-+13.22%-1.54%+142.16%+54.16%+29.96%-2.82%+1.84%-2.52%+10.53%+32.69%+11.32%+11.11%+4.76%-22.22%+24.79%+10.19%+12.93%+12.12%
Cost of Revenue10.28M15.14M15.83M30.20M40.20M49.98M44.22M56.31M54.11M55.84M70.74M73.00M77.45M85.69M73.31M82.64M87.03M90.99M104.05M
Gross Profit3.16M70.83K-847.15K6.07M15.72M22.69M26.41M15.62M16.00M21.65M32.09M41.47M49.74M47.55M30.33M46.70M55.49M69.97M76.41M
Gross Margin23.52%0.47%-5.66%16.74%28.11%31.23%37.39%21.72%22.83%27.94%31.21%36.23%39.11%35.69%29.26%36.11%38.94%43.47%42.34%
Operating Expense19.48M17.11M15.53M16.81M18.04M18.45M22.71M26.52M27.43M27.49M24.64M22.21M26.95M28.32M31.02M42.17M45.43M49.92M50.17M
Operating Income-16.32M-17.04M-16.37M-10.73M-2.32M4.24M3.70M-10.90M-11.42M-5.84M7.44M19.26M22.78M19.24M-696.00K4.53M10.06M20.05M26.23M
Operating Margin-121.42%-112.02%-109.31%-29.59%-4.14%5.83%5.24%-15.16%-16.29%-7.54%7.24%16.82%17.91%14.44%-0.67%3.50%7.06%12.46%14.54%
EBITDA-20.33M-14.67M-15.52M-9.38M2.72M7.18M8.09M-8.31M-7.10M-1.98M11.25M23.46M27.79M25.41M4.01M10.81M21.20M27.80M39.25M
EBITDA Margin-151.27%-96.45%-103.61%-25.86%4.86%9.88%11.45%-11.55%-10.12%-2.56%10.94%20.50%21.85%19.07%3.87%8.36%14.87%17.27%21.75%
Net Income-22.90M-12.45M-22.03M-15.17M-3.49M260.00K443.00K-12.64M-11.27M-6.73M6.90M22.30M22.25M17.14M-2.23M-2.32M8.28M14.46M20.20M
Net Income Margin-170.39%-81.81%-147.09%-41.83%-6.25%0.36%0.63%-17.57%-16.07%-8.69%6.71%19.48%17.49%12.86%-2.15%-1.79%5.81%8.99%11.19%
R&D-12.37M-9.76M11.03M11.82M12.74M16.03M16.53M16.25M11.97M9.75M13.06M13.61M11.36M13.17M13.93M15.19M12.99M
R&D as % of Total Revenue-81.33%-26.91%19.72%16.27%18.05%22.29%23.58%20.96%11.64%8.51%10.27%10.21%10.96%10.18%9.78%9.43%7.20%
Interest Expense442.71K4.60M4.04M5.03M3.79M3.35M3.15M3.03M934.00K126.00K82.00K327.13K293.00K266.00K283.00K914.00K1.30M660.00K864.00K
Interest Expense % of Total Revenue3.29%30.21%26.97%13.86%6.78%4.62%4.46%4.21%1.33%0.16%0.08%0.29%0.23%0.20%0.27%0.71%0.91%0.41%0.48%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-42.06M62.91M91.52M85.45M89.11M139.38M119.62M101.99M99.70M122.11M138.12M173.80M210.66M318.67M322.38M354.91M372.25M378.79M
Total Liabilities-29.42M32.76M65.03M62.78M60.72M49.41M38.63M29.48M32.95M32.62M25.74M38.48M32.03M141.84M146.36M110.89M112.79M109.66M
Total Equity-12.64M30.15M26.49M22.67M28.39M89.97M80.99M72.51M66.74M89.49M112.38M135.32M178.64M176.82M176.02M244.02M259.46M269.13M
Cash-13.28M30.38M25.72M24.47M16.87M59.11M14.55M5.05M9.97M12.68M18.09M42.66M70.20M18.59M34.26M55.64M78.44M75.48M
Total Debt-20.32M21.00M23.18M22.53M24.12M16.22M7.49M188.00K1.78M1.98M1.28M5.75M4.94M24.35M20.60M8.82M11.06M11.56M
Net Debt-7.05M-9.38M-2.54M-1.94M7.25M-42.89M-7.05M-4.86M-8.19M-10.70M-16.82M-36.91M-65.26M5.76M-13.66M-46.82M-67.37M-63.92M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.57M-12.72M-13.09M10.63M940.36K-8.26M-3.85M-9.92M-13.98M1.90M3.89M10.55M28.44M19.11M-9.17M28.59M4.32M47.59M27.59M
Investing Cash Flow-7.14M-3.60M-5.81M-23.34M-1.11M-2.43M-3.90M-26.82M11.25M1.64M-15.89M-5.18M-581.80K-13.13M-63.46M-3.78M-5.84M-10.74M-10.65M
Financing Cash Flow14.26M25.21M36.02M7.57M-378.88K2.97M49.21M-7.64M-6.36M1.49M15.32M-587.00K-1.58M23.36M19.33M-9.34M22.68M-13.91M-19.86M
Capital Expenditure7.62M3.73M5.27M3.84M1.86M4.61M5.64M3.08M2.72M2.64M4.45M2.88M2.37M5.49M3.88M3.78M5.85M10.74M10.66M
Free Cash Flow-20.19M-16.45M-18.36M6.80M-922.75K-12.87M-9.50M-12.99M-16.70M-744.00K-559.00K7.66M26.07M13.62M-13.04M24.80M-1.53M36.85M16.93M
Dividends Paid----------------0012.49M
FCF to OCF160.60%129.30%140.26%63.92%-98.13%155.79%246.42%131.01%119.44%-39.22%-14.37%72.65%91.66%71.27%142.30%86.76%-35.57%77.43%61.37%
Dividend Paid to FCF----------------0.00%0.00%73.73%

Earnings

Report DateDec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Feb 27, 2013May 5, 2013Aug 1, 2013Oct 29, 2013Feb 5, 2014May 8, 2014Aug 14, 2014Nov 12, 2014Feb 11, 2015May 12, 2015Jul 30, 2015Nov 10, 2015Feb 2, 2016May 9, 2016Aug 2, 2016Nov 10, 2016Feb 6, 2017May 16, 2017Aug 1, 2017Nov 13, 2017Feb 7, 2018May 15, 2018Aug 7, 2018Nov 12, 2018Feb 12, 2019May 14, 2019Aug 6, 2019Nov 13, 2019Feb 12, 2020May 18, 2020Aug 12, 2020Nov 11, 2020Feb 10, 2021May 12, 2021Aug 11, 2021Nov 22, 2021Mar 15, 2022May 17, 2022Aug 17, 2022Nov 22, 2022Mar 15, 2023May 24, 2023Aug 16, 2023Nov 13, 2023Mar 6, 2024May 8, 2024Aug 14, 2024Nov 13, 2024Mar 4, 2025May 14, 2025Aug 13, 2025Nov 10, 2025Mar 18, 2026May 13, 2026Aug 12, 2026Nov 9, 2026
EPS Estimate-------0.04-0.010.06-0.04-0.05-0.060.01-0.03-0.02-0.040.03-0.01-0.02-0.07-0.09-0.020.13-0.010.100.040.04-0.020.190.010.170.090.140.050.120.090.100.070.060.02-0.010.03-0.02-0.030.070.040.030.020.050.070.060.070.050.070.090.090.100.120.120.13
EPS Actual0.14-0.02-0.09-0.040.11-0.070.050.000.05-0.06-0.23-0.090.05-0.15-0.06-0.130.03-0.05-0.02-0.03-0.05-0.110.13-0.010.160.030.14-0.060.450.120.150.140.120.120.080.150.040.050.02-0.02-0.11-0.04-0.050.050.07-0.040.040.060.090.040.080.070.070.070.130.090.060.070.16-
Surprise------225.00%111.00%-16.67%-50.00%-360.00%-50.00%400.00%-400.00%-200.00%-225.00%0.00%-400.00%0.00%57.14%44.44%-450.00%0.00%0.00%60.00%-25.00%250.00%-200.00%136.84%1100.00%-11.76%55.56%-14.29%140.00%-33.33%66.67%-60.00%-28.57%-66.67%-200.00%-1000.00%-233.33%-150.00%266.67%0.00%-200.00%33.33%200.00%80.00%-42.86%33.33%0.00%31.33%0.00%44.44%0.00%-40.00%-41.67%33.33%-
Timing-----After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap503.23M
Enterprise Value452.39M
Trailing P/E22.95
Forward P/E16.53
PEG Ratio0.66
Price / Sales2.62
Price / Book1.90
EPS0.38
Book Value4.66
Revenue (TTM)191.85M
Gross Profit (TTM)78.31M
EBITDA41.49M
Profit Margin11.60%
Operating Margin17.32%
Return on Equity8.41%
Return on Assets4.63%
Shares Outstanding57.71M
Shares Float31.77M
Beta0.14
Dividend Yield1.95%
Dividend Rate0.17
Payout Ratio110.53%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 13.50
  • Strong Buy
    2
  • Buy
    1

Ownership Breakdown

Institutions
49.17%
Insiders
7.03%
Retail / Other
43.80%

Top Institutional Holders

  • Phoenix Financial Ltd
    1.65M2.87%
  • Two Sigma Investments LLC
    151.10K0.26%
  • Altshuler Shaham Ltd
    20.56K0.04%
  • Citadel Advisors Llc
    14.45K0.03%

Top Fund Holders

  • DFA International Core Equity 2 I
    98.55K0.17%
  • Dimensional International Sm Cp Val ETF
    65.12K0.11%
  • Dimensional International Small Cap ETF
    52.92K0.09%
  • iShares Nasdaq US Biotech ETF USD Acc
    48.86K0.08%
  • DFA International Small Cap Value I
    45.90K0.08%
  • Fidelity Nasdaq Composite Index
    37.50K0.07%
  • Dimensional International Core Eq 2 ETF
    35.80K0.06%
  • Dimensional Global Trgtd Value USD Acc
    25.94K0.04%
  • Mandarine Global Microcap G EUR
    25.00K0.04%
  • Acuitas Small Cap Active ETF
    24.57K0.04%
  • Dimensional World ex US Core Eq 2 ETF
    20.16K0.03%
  • Dimensional International Cr Eq Mkt ETF
    9.87K0.02%
  • China Universal NASDAQ Bio-Tch ETF(QDII)
    9.18K0.02%
  • DFA World ex US Core Equity Instl
    8.91K0.02%
  • DFA International Vector Equity I
    8.37K0.01%
  • DFA World ex US Targeted Val Instl
    7.36K0.01%

Dividends

20262×
0.17Aug 27, 20260.25Mar 23, 2026
20251×
0.20Mar 17, 2025
20131×
0.01Jun 13, 2013

Stock Splits

  • Aug 25, 20101019:1000